Back to search results

Microdialysis During Neurosurgery for Brain Tumors

This study is looking at how well a procedure called microdialysis works during brain surgery for people with brain tumors like glioma, glioblastoma, or metastatic brain cancer. Microdialysis uses a small catheter to collect tiny samples from the brain during surgery. Researchers want to see if this method can help find "biomarkers" (measurable indicators of disease) that could lead to better ways to diagnose, monitor, and treat these tumors. You might be able to join if you are 18 or older and are scheduled for brain surgery for a suspected or diagnosed brain tumor or epileptic focus. The study will measure any side effects and look for specific substances in the samples for up to 42 days after surgery.

Study design
This interventional study plans to enroll 100 participants. It is not specified if it's randomized or blinded.
What's involved
You would undergo microdialysis during your standard surgery and have an MRI. You would then be followed for 42 days after the study procedures.
Compensation
Not stated in the trial record.
Follow-up
You will be followed up for 42 days after the study procedures are completed.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04047264

Feasibility of Intra- and Post-operative Microdialysis During Neurosurgery for Central Nervous System Lesions

Recruiting
NAAges 18+InterventionalBasic science
Mayo Clinic
~100 participants
Updated 2026-08-18 on ClinicalTrials.gov
What's tested:MicrodialysisMagnetic Resonance ImagingComputed Tomography

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of adverse events
Measured over Up to 42 days
+1 more outcome measured

Conditions

Glioma
Glioblastoma
Metastatic Malignant Neoplasm in the Brain

Explore related trials

Brain NeoplasmGliomaSeizure Disorder

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Terence C Burns, MD, PhD · PRINCIPAL_INVESTIGATOR · Mayo Clinic in Rochester

Who to contact

Clinical Trials Referral Office
[email protected]
855-776-0015
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age \>= 18 years
Diagnosis of the following, based on clinical and radiographic evidence:
Any glioma
Metastatic brain tumor of any primary origin
Epileptic focus requiring surgical resection
Planned neurosurgical procedure for purposes of biopsy or resection of suspected or previously diagnosed brain tumor (primary or metastatic) or epileptic focus as part of routine clinical care
Willing to undergo neurosurgical resection or biopsy at Mayo Clinic \[Rochester, Minnesota (MN)\]
For patients with gliomas recruited for post-operative microdialysis, willingness to stay in the hospital through post-operative day (POD) 3-5 (timing per physician and patient's shared decision making)
Ability to understand and the willingness to sign a written informed consent document
Enrollment into the Biobank study (IRB#12-003458)

Exclusion

Vulnerable populations: pregnant women, prisoners or the mentally handicapped
Patients who are not appropriate candidates for surgery due to current or past medical history or uncontrolled concurrent illness

What this trial measures

  • Incidence of adverse eventsUp to 42 days

    Will be assessed by evaluating the proportion of patients who: (2) develop persistent adverse events deemed related (possibly, probably, definitely) to the insertion or use of microdialysate catheters. Attribution of neurologic deficit will typically be considered unlikely unless there is evidence of intra-operative intracranial hemorrhage that the surgeon deems to be attributable to use of the microdialysis catheter. Adverse events will be measured by Common Terminology Criteria for Adverse Events 5.0.

  • Targeted metabolomicsUp to 42 days

    Metabolites within each region of tumor to brain-adjacent-to tumor within a patient compared. Metabolites from patients without central nervous system malignancies averaged across the epileptic foci group and descriptively compared to the areas from patients with gliomas.